Colorado Wins Federal Approval for Plan to Import Prescription Drugs from Canada

Colorado has become the second U.S. state to receive federal approval from the Food and Drug Administration to import lower-cost prescription drugs from Canada. The program aims to save consumers and private insurers an estimated $46.2 million over its first three years by targeting 20 specific medications from 10 different manufacturers. This development marks a significant shift in state-level efforts to bypass traditional pharmaceutical pricing structures, though the program faces substantial logistical and political hurdles before implementation.

Colorado’s Department of Health Care Policy and Financing secured FDA authorization to establish a drug importation channel after a seven-year planning and application process. To gain approval, the state had to coordinate a Canadian buyer and a U.S. importer while implementing systems for laboratory testing and relabeling to verify drug authenticity and safety. The program initially targets 20 medications, including high-demand drugs like Ozempic and Eliquis, as well as the leukemia drug Sprycel. State officials highlight Sprycel as a primary example of potential savings, noting it could be delivered to Coloradans for 68% less than current domestic prices, with three other drugs expected to see at least a 50% price reduction.

The state estimates the importation program will save consumers and private insurers approximately $46.2 million over its first three years of operation. These savings are primarily intended for individuals with private health insurance, as the state’s Medicaid budget already benefits from federal pricing controls similar to Canadian levels. Governor Jared Polis emphasized that the initiative seeks to address a pricing gap where Americans pay significantly more for medications produced in the same factories as those sold abroad. However, the program's success depends on the state's ability to persuade pharmaceutical companies to cooperate, a task that has proven difficult as manufacturers currently have the option to refuse participation in favor of higher-priced domestic sales.

Significant hurdles remain, including opposition from the Canadian government, which has vowed to block exports that could trigger domestic drug shortages or worsen existing supply issues. Furthermore, pharmaceutical manufacturers have shown little interest in participating; state records indicate that of 23 manufacturers contacted during the application process, none agreed to join. Companies such as Viiv Healthcare have explicitly rejected the program, citing risks to supply chain integrity, while others like Gilead Sciences engaged in discussions that ultimately failed to produce an agreement. Colorado now follows Florida as the second state to receive such approval, though Florida’s program has remained stalled since 2024 without successfully importing any medication.